- Conditions
- B-Cell Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- Glofitamab, Obinutuzumab (G), Rituximab (R), Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 39
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mature B-Cell Non-Hodgkin Lymphoma
- Interventions
- Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin, Etoposide, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 6 Months to 30 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Oakland, California • Roseville, California + 6 more
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Glofitamab, Obinutuzumab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 940 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 6
- States / cities
- Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Fresno, California • Jacksonville, Florida + 6 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography, FDG-Positron Emission Tomography, Glofitamab, Ibrutinib, Magnetic Resonance Imaging, Obinutuzumab
- Procedure · Biological · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma
- Interventions
- mosunetuzumab, glofitamab, obinutuzumab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 2
- States / cities
- Omaha, Nebraska • Philadelphia, Pennsylvania
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- SC Mosunetuzumab, IV Glofitamab, Iberdomide, Golcadomide, Obinutuzumab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 6
- States / cities
- San Francisco, California • Aurora, Colorado • Tampa, Florida + 3 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Acalabrutinib, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Glofitamab, Multigated Acquisition Scan, Obinutuzumab, Positron Emission Tomography
- Drug · Procedure · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell
- Interventions
- Tafasitamab, Polatuzumab vedotin, Glofitamab, Obinutuzumab
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Mantle Cell Lymphoma, MCL
- Interventions
- Glofitamab, Obinutuzumab, Lenalidomide
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 7 more
- Conditions
- Relapsed/Refractory Non-Hodgkin Lymphoma
- Interventions
- BMS-986458, Rituximab, Glofitamab/Obinutuzumab, Mosunetuzumab, Epcoritamab, Golcadomide
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Duarte, California • Jacksonville, Florida + 7 more
- Conditions
- Lymphoma
- Interventions
- Glofitamab, Tocilizumab, Obinutuzumab, Gemcitabine, Oxaliplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Santa Monica, California • Orlando, Florida • Chicago, Illinois + 5 more
- Conditions
- Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Glofitamab, Lumbar Puncture, Magnetic Resonance Imaging, Obinutuzumab, Positron Emission Tomography
- Procedure · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Large B-Cell Lymphoma
- Interventions
- Glofitamab, Polatuzumab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 60
- States / cities
- Anchorage, Alaska • Anaheim, California • Clovis, California + 49 more
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Glofitamab, Lenalidomide, Obinutuzumab, Positron Emission Tomography, Venetoclax
- Procedure · Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Duarte, California • New York, New York • Salt Lake City, Utah
- Conditions
- Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Glofitamab, Obinutuzumab, Positron Emission Tomography
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 11
- States / cities
- Duarte, California • Atlanta, Georgia • Lexington, Kentucky + 6 more
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Englumafusp alfa, Obinutuzumab, Glofitamab, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 4
- States / cities
- Pasadena, California • San Francisco, California • St Louis, Missouri + 1 more
- Conditions
- Chronic Lymphocytic Leukemia, Richter's Transformation
- Interventions
- Glofitamab, Obinutuzumab, Polatuzumab Vedotin, Atezolizumab, Tocilizumab, Pirtobrutinib
- Drug
- Lead sponsor
- Christine Ryan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Chapel Hill, North Carolina + 1 more
- Conditions
- Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
- Interventions
- Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 33
- States / cities
- Anchorage, Alaska • Clovis, California • Fullerton, California + 29 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Obinutuzumab, Glofitamab, Pirtobrutinib, Tumor Imaging, Biospecimen Collection, ClonoSeq Assay, Bone Marrow Biopsy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Davis, California • Los Angeles, California • San Diego, California + 1 more
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- maplirpacept (PF-07901801), Glofitamab, Obinutuzumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Kansas City, Kansas • St Louis, Missouri
- Conditions
- B-cell Lymphoma
- Interventions
- Glofitamab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, B-cell Lymphomas, Relapsed/Refractory Large B-cell Lymphoma, Large B-cell Lymphoma
- Interventions
- Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin, Leukapheresis, Lymphodepleting chemotherapy, LISOCABTAGENE MARALEUCEL
- Drug · Procedure
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma
- Interventions
- Obinutuzumab, Glofitamab
- Drug
- Lead sponsor
- Reid Merryman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York